NIH nixes support for Pluri’s radiation exposure cell therapy amid cost-cutting drive
The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. Having put up funding to help bring the candidate to market, the government terminated the contract in a move that Pluri believes “may reflect broader federal budgetary and administrative adjustments."
The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. Having put up funding to help bring the candidate to market, the government terminated the contract in a move that Pluri believes “may reflect broader federal budgetary and administrative adjustments."
